1. EZH2 GAIN‐OF‐FUNCTION MUTATIONS ARE NOT ASSOCIATED WITH MORE FAVORABLE PROGNOSIS IN RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA (FL): A PRELIMINARY ANALYSIS ON 590 PATIENTS. (12th June 2019) Authors: Okosun, J.; Bödör, C.; Batlevi, C.; Nagy, N.; Michot, J.; Schneider, T.; Alizadeh, H.; Simon, Z.; Vose, J.; Younes, A.; Ribrag, V.; Fitzgibbon, J.; Yang, J.; Agarwal, S.; Newberry, K.J.; Michaud, N.R. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 192 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. FEASIBILITY AND BENEFIT OF MOLECULARLY‐INFORMED ENROLLMENT INTO EARLY PHASE CLINICAL TRIALS FOR PATIENTS WITH RELAPSED OR REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA. (12th June 2019) Authors: Michot, J.; Camara‐Clayette, V.; Detolle, A.; Chahine, C.; Lazarovici, J.; Danu, A.; Bosq, J.; Ghez, D.; Romano‐Martin, P.; Dartigues, P.; Arfi‐Rouche, J.; Bahleda, R.; Rahali, W.; Varga, A.; Baldini, C.; Tselikas, L.; Paume, C.; Lecourt, H.; Cotteret, S.; Vergé, V. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 330 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. Molecular landscape of relapse/refractory diffuse large B‐cell lymphoma. (June 2017) Authors: Michot, J.; Camara‐Clayette, V.; Chahine, C.; Lazarovici, J.; Bosq, J.; Ghez, D.; Dartigues, P.; Danu, A.; Arfi‐Rouche, J.; Tselikas, L.; Ba, B.; Cotteret, S.; Rahali, W.; Vergé, V.; Ribrag, V. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 279 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. PHASE 1B KEYNOTE‐013 STUDY OF PEMBROLIZUMAB IN PATIENTS WITH CLASSIC HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE: RESULTS OF >4 YEARS OF FOLLOW‐UP. (12th June 2019) Authors: Zinzani, P.L.; Armand, P.; Ribrag, V.; Michot, J.; Kuruvilla, J.; Zhu, Y.; Farooqui, M.; Nahar, A.; Moskowitz, C.H. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 296 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. PHASE 1B STUDY OF PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (RRPMBCL): UPDATED RESULTS FROM THE KEYNOTE‐013 TRIAL. (June 2017) Authors: Zinzani, P.; Ribrag, V.; Moskowitz, C.H.; Michot, J.; Kuruvilla, J.; Bartlett, N.; Balakumaran, A.; Chatterjee, A.; Chlosta, S.; Shipp, M.A.; Armand, P. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 189 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. PV-0208 Immune-related pneumonitis in NSCLC patients treated with ICI: impact of previous thoracic RT. (April 2019) Authors: Botticella, A.; Ibrahim, T.; Mezquita, L.; Hendriks, L.; Le Pavec, J.; Ferrara, R.; Caramella, C.; Champiat, S.; Michot, J.; Lavaud, P.; Gustin, P.; Planchard, D.; Gazzah, A.; Marabelle, A.; Deutsch, E.; Besse, B.; Le Pechoux, C. Journal: Radiotherapy and oncology Issue: Volume 133(2019)Supplement 1 Page Start: S109 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. SAFETY PROFILE OF COMBINATION THERAPY WITH IMMUNE CHECKPOINT BLOCKERS AND VEGF INHIBITORS IN OLDER PATIENTS TREATED IN EARLY PHASE CLINICAL TRIALS. (November 2019) Authors: Baldini, C.; Romano, P.Martin; Vincent, H.; Vuagnat, P.; Champiat, S.; Michot, J.; Bahleda, R.; Gazzah, A.; Vinay, S.Postel; Hollebecque, A.; Angevin, E.; Ribrag, V.; Loriot, Y.; Marabelle, A.; Massard, C.; Varga, A. Journal: Journal of geriatric oncology Issue: Volume 10(2019)Supplement 1 Page Start: S108 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗